Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Applied Molecular Transport Inc. AMTI NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.70
+546.4%

Applied Molecular Transport Inc. (AMTI) is a Biotechnology company in the Healthcare sector, currently trading at $0.26. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is AMTI = $2 (+546.4% upside).

Net income is $125M (loss), growing at -69.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $36M against $61M equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 4.24 (strong liquidity). Debt-to-assets is 33.6%. Total assets: $107M.

Analyst outlook: 0 / 5 analysts rate AMTI as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$1.70
▲ 546.39% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Applied Molecular Transport Inc., the average price target is $1.70, with a high forecast of $3.00, and a low forecast of $0.40.
Highest Price Target
$3.00
Average Price Target
$1.70
Lowest Price Target
$0.40

AMTI SharesGrow Score Overview

54/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AMTI

✓
VALUE Pass
100/100
AMTI trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying +660.5% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
AMTI: +0%/yr revenue is, -69.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet AMTI: Debt-to-Equity (D/E) ratio 0.59 (moderate), Current ratio is 4.24 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
AMTI: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 0 / 5 analysts rate AMTI as buy (0%). Analyst consensus target is $2 (+660.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.1343-0.84
Volume235.21K
Avg Volume (30D)320.2K
Market Cap$11.01M
Beta (1Y)2.29
Share Statistics
EPS (TTM)-3.23
Shares Outstanding$38.84M
IPO Date2020-06-05
Employees13
CEOShawn M. Cross
Financial Highlights & Ratios
EBITDA$-127.22M
Net Income$-125.43M
Operating Income$-127.22M
Total Cash$61.15M
Total Debt$36.12M
Net Debt$-25.02M
Total Assets$107.45M
Price / Earnings (P/E)-0.1
Analyst Forecast
1Y Price Target$1.70
Target High$3.00
Target Low$0.40
Upside+546.4%
Rating ConsensusHold
Analysts Covering5
Buy 0% Hold 60% Sell 40%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS03824M1099

Price Chart

Track all markets on TradingView
AMTI
Applied Molecular Transport Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.13 52WK RANGE 0.84

People Also View

CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.92
+3.28%
 BNTC
BNTC
Benitec Biopharma Inc.
$13.25
+10.42%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 FENC
FENC
Fennec Pharmaceuticals Inc.
$6.25
+5.40%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
 IKT
IKT
Inhibikase Therapeutics, Inc.
$1.70
-0.58%
 ANTX
ANTX
AN2 Therapeutics, Inc.
$2.98
-1.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message